Related Experiment Video
Updated: Feb 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Demystifying biosimilars: development, regulation and clinical use
Hope S Rugo1, Robert M Rifkin2, Paul Declerck3
1Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA.
Abstract:
Biologics are an integral component in the treatment of various diseases. However, limited patient access to these medicines remains a significant global challenge, prompting development of safe and effective biosimilars. A biosimilar is 'highly similar to a reference (originator) product, for which there are no clinically meaningful differences between the two products in terms of safety, purity and potency'. Biosimilars have the potential to offer possible benefits, including lower treatment costs, thereby increasing patient access and clinical use, which may lead to better overall outcomes. Improved understanding of biosimilars may enhance confidence and trust in these agents. As increasing numbers of biosimilars achieve regulatory approval, this overview aims to address enduring knowledge gaps regarding the development and use of biosimilars.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Epigenetic Regulation
Master Transcription Regulators
GTPases and their Regulation
Large G-proteins,...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Negative Regulator Molecules

